News
Ultragenyx Pharmaceutical Inc. shares plunged 30% as UX143 trial raises efficacy doubts. Click for more on RARE and my ...
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO), today announced that the randomized, placebo-controlled Phase ...
About the Setrusumab Phase 3 Program Ultragenyx is developing setrusumab in pediatric and young adult patients across OI sub-types I, III and IV with two late-stage studies: the pivotal Phase 2/3 ...
The British energy major said Friday that it anticipates booking $500 million to $1.5 billion in after-tax impairment charges alongside its second-quarter earnings. These charges are considered ...
BP's second-quarter results will be hit by lower prices it received for its gas and oil, it said in a quarterly trading ...
BP Plc has put an oil and gas revival at the heart of its turnaround plan, and upstream chief Gordon Birrell is leading the ...
Nvidia reaches $4T market cap, solidifying its dominance in the AI revolution. Discover insights, stock analysis, and more in ...
Edition Adds AI-generated Customer Feedback Summaries and Platform GraphicsSTAMFORD, Conn., July 10, 2025 (GLOBE NEWSWIRE) -- BP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results